Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relfydess versus Alluzience for moderate to severe glabellar lines
RBR-10tkjh3tPhase 3Completed
- Sponsor
- Uningá
- Start
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of relugolix + estradiol + norethindrone and alluzience in glabellar furrowing (2 arms), sponsored by Uningá. Primary endpoint: Efficacy of glabellar line treatment. Started Feb 2026; status: completed.
02
Drugs
relugolix + estradiol + norethindronealluzience
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on RBR-10tkjh3t.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-10tkjh3t.